The handle http://hdl.handle.net/1887/66672 holds various files of this Leiden University dissertation.

**Author:** Schneider, T.C.
**Title:** Novel treatments for advanced thyroid cancer and elucidation of biomarkers
**Issue Date:** 2018-10-31
Stellingen

behorende bij het proefschrift

Novel treatments for advanced thyroid cancer and elucidation of biomarkers

1. The presence of bone metastases significantly influences the outcome in patients treated with sorafenib for advanced thyroid carcinoma. (this thesis)

2. Sorafenib is potentially involved in the tumorigenesis of secondary non-cutaneous squamous cell carcinoma. (this thesis)

3. Everolimus is a good candidate for individualized dosing in patients with cancer. (this thesis)

4. In the treatment of thyroid cancer patients, everolimus has a relatively low toxicity profile but a disease control rate comparable to sorafenib. (this thesis)

5. Nowadays ‘less becomes more’ in the treatment of papillary microcarcinoma.

6. In the treatment of malignancies, having the focus on underlying gene mutations is too simplistic.

7. Advanced thyroid cancer, except for anaplastic carcinoma, is an indolent disease in most cases and a wait-and-see-policy is often possible for some period.

8. Privatization of healthcare and a system with private health insurance goes at the expense of patient care.


10. Manchmal is alles einfach, und dann wieder net. (Wolfgang Ambros, 1986) Sometimes everything is easy, and then again it’s not.